FIELD: pharmacology.
SUBSTANCE: diflunisal co-crystalline form with isoniazid is disclosed, wherein the molar ratio of diflunisal to isoniazid is 1:1, wherein the cocrystal has an endothermic spike from 148 to 152°C, according to measurement by differential scanning calorimetry, and spikes at 2θ(°) 5.9, 7.5, 8.5, 11.6, 15.1, 18.5, 26.6, according to measurement by powder X-ray diffraction.
EFFECT: diflunisal co-crystalline form is obtained, suitable for use in the pharmaceutical industry as a pharmaceutical preparation component, used to relieve pain accompanied by inflammation, and symptomatic treatment of rheumatoid arthritis and osteoarthritis, with increased level of solubility in water by more than 5 times for diflunisal compared with values in pure form.
7 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CO-CRYSTALLINE FORM OF ISONIAZID | 2016 |
|
RU2630957C1 |
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
| CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
| COCRYSTALLINE FORM OF FENBUFEN | 2012 |
|
RU2521572C1 |
| HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
| COCRYSTALLINE FORM OF 1-[5-(4-CHLOROPHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2018 |
|
RU2712443C1 |
